{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:46:45Z","timestamp":1776761205024,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neuropharm.2026.110940","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:35:15Z","timestamp":1774542915000},"page":"110940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting ME1 rescues redox-metabolic coordination in ALS: A core effector of NRF2-directed therapy"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2731-8142","authenticated-orcid":false,"given":"Yifan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengmin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangxia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b1","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/molecules27051471","article-title":"Activation of the nrf2 pathway as a therapeutic strategy for als treatment","volume":"27","author":"Arslanbaeva","year":"2022","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110940_b2","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402853","article-title":"Activation of the Keap1\/Nrf2 pathway suppresses mitochondrial dysfunction, oxidative stress, and motor phenotypes in C9orf72 ALS\/FTD models","volume":"7","author":"Au","year":"2024","journal-title":"Life Sci. Alliance"},{"issue":"11\u201312","key":"10.1016\/j.neuropharm.2026.110940_b3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbadis.2006.03.008","article-title":"Oxidative stress in als: a mechanism of neurodegeneration and a therapeutic target","volume":"1762","author":"Barber","year":"2006","journal-title":"Biochim. Biophys. Acta (BBA)-Molecular Basis Dis."},{"issue":"23","key":"10.1016\/j.neuropharm.2026.110940_b4","doi-asserted-by":"crossref","first-page":"16833","DOI":"10.3390\/ijms242316833","article-title":"Mitochondrial dyshomeostasis as an early hallmark and a therapeutic target in amyotrophic lateral sclerosis","volume":"24","author":"Belosludtseva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13024-021-00479-8","article-title":"Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy","volume":"16","author":"Bono","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.110940_b6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s00415-009-5100-z","article-title":"Hypermetabolism in als patients: an early and persistent phenomenon","volume":"256","author":"Bouteloup","year":"2009","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110940_b7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/metabo12030233","article-title":"Mechanistic insights of mitochondrial dysfunction in amyotrophic lateral sclerosis: an update on a lasting relationship","volume":"12","author":"Candelise","year":"2022","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110940_b8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/aja.1001940306","article-title":"Neuroblastoma\u00d7 spinal cord (nsc) hybrid cell lines resemble developing motor neurons","volume":"194","author":"Cashman","year":"1992","journal-title":"Dev. Dyn."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.110940_b9","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13798","article-title":"Redox profiles of amyotrophic lateral sclerosis lymphoblasts with or without known SOD1 mutations","volume":"52","author":"Cunha-Oliveira","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","article-title":"Energy metabolism in amyotrophic lateral sclerosis","volume":"10","author":"Dupuis","year":"2011","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1046\/j.1471-4159.2000.0741895.x","article-title":"Development and characterisation of a glutamate-sensitive motor neurone cell line","volume":"74","author":"Eggett","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2026.110940_b12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2018.07.005","article-title":"Autophagy and mitophagy in als","volume":"122","author":"Evans","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"7504","key":"10.1016\/j.neuropharm.2026.110940_b13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature13236","article-title":"Quantitative flux analysis reveals folate-dependent nadph production","volume":"510","author":"Fan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.110940_b14","first-page":"1","article-title":"Glucose metabolic reprogramming in microglia: implications for neurodegenerative diseases and targeted therapy","author":"Fang","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.expneurol.2011.09.020","article-title":"Absence of SOD1 leads to oxidative stress in peripheral nerve and causes a progressive distal motor axonopathy","volume":"233","author":"Fischer","year":"2012","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.neuropharm.2026.110940_b16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41582-023-00867-2","article-title":"The amyotrophic lateral sclerosis exposome: recent advances and future directions","volume":"19","author":"Goutman","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/WCO.0000000000000982","article-title":"Dysregulation of energy homeostasis in amyotrophic lateral sclerosis","volume":"34","author":"Guillot","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4103\/1673-5374.382985","article-title":"Pathological mechanisms of amyotrophic lateral sclerosis","volume":"19","author":"Hu","year":"2024","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuropharm.2026.110940_b19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075037","article-title":"Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis","volume":"383","author":"Ilieva","year":"2023","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"Nadph homeostasis in cancer: functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110940_b21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s12035-023-03559-6","article-title":"Nrf2 signaling pathway: a potential therapeutic target in combating oxidative stress and neurotoxicity in chemotherapy-induced cognitive impairment","volume":"61","author":"Lal","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110940_b22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/biomedicines10061307","article-title":"Metabolic profile and pathological alterations in the muscle of patients with early-stage amyotrophic lateral sclerosis","volume":"10","author":"Lanznaster","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/ars.2012.4754","article-title":"The predicted molecular weight of Nrf2: it is what it is not","volume":"18","author":"Lau","year":"2013","journal-title":"Antioxidants Redox Signal."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110940_b24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.31761","article-title":"Adaptive and constitutive activations of malic enzymes confer liver cancer multilayered protection against reactive oxygen species","volume":"74","author":"Lee","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41401-023-01223-2","article-title":"Desloratadine alleviates als-like pathology in hsod1g93a mice via targeting 5htr2a on activated spinal astrocytes","volume":"45","author":"Lu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110940_b26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.110940_b27","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1007\/s11064-021-03366-2","article-title":"Nrf2\/ho-1 signaling activator acetyl-11-keto-beta boswellic acid (akba)-mediated neuroprotection in methyl mercury-induced experimental model of als","volume":"46","author":"Minj","year":"2021","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2026.110940_b28","doi-asserted-by":"crossref","unstructured":"Murakami, S., Kusano, Y., Okazaki, K., Akaike, T., Motohashi, H., Nrf2 signalling in cytoprotection and metabolism. Br. J. Pharmacol. 2023.","DOI":"10.22541\/au.168872044.49044735\/v1"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110940_b29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s13311-022-01262-3","article-title":"Altered bioenergetics and metabolic homeostasis in amyotrophic lateral sclerosis","volume":"19","author":"Nelson","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10.1016\/j.neuropharm.2026.110940_b30","doi-asserted-by":"crossref","first-page":"14966","DOI":"10.1007\/s12035-025-05067-1","article-title":"SOD1, A crucial protein for neural biochemistry: Dysfunction and risk of amyotrophic lateral sclerosis","volume":"62","author":"Neto","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.110940_b31","first-page":"1","article-title":"Sod1, a crucial protein for neural biochemistry: Dysfunction and risk of amyotrophic lateral sclerosis","author":"Neto","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110940_b32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/0118715273315891240801065231","article-title":"Amyotrophic lateral sclerosis (als): an overview of genetic and metabolic signaling mechanisms","volume":"24","author":"Nogueira-Machado","year":"2025","journal-title":"CNS Neurol. Disorders-Drug Targets"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41419-025-07584-2","article-title":"Mitochondrial and energy metabolism dysfunctions are hallmarks of tdp-43g376d fibroblasts from members of an amyotrophic lateral sclerosis family","volume":"16","author":"Perciballi","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b34","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/s41467-025-59679-1","article-title":"Single-cell rna-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across fus-and tardbp-als","volume":"16","author":"Schweingruber","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.110940_b35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/ph15060692","article-title":"A pivotal role of nrf2 in neurodegenerative disorders: a new way for therapeutic strategies","volume":"15","author":"Suzen","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2026.110940_b36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fnins.2016.00611","article-title":"Metabolic dysfunctions in amyotrophic lateral sclerosis pathogenesis and potential metabolic treatments","volume":"10","author":"Tefera","year":"2017","journal-title":"Front. Neurosci."},{"issue":"18","key":"10.1016\/j.neuropharm.2026.110940_b37","first-page":"5196","article-title":"Identification of nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray","volume":"62","author":"Thimmulappa","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110940_b38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41583-022-00564-x","article-title":"Modelling amyotrophic lateral sclerosis in rodents","volume":"23","author":"Todd","year":"2022","journal-title":"Nature Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.110940_b39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00401-018-1835-x","article-title":"Energy metabolism in als: an underappreciated opportunity?","volume":"135","author":"Vandoorne","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2026.110940_b40","series-title":"Misfolded sod1 associated with motor neuron","author":"Velde","year":"2011"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110940_b41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11306-025-02267-7","article-title":"Metabolomics: a new frontier in neurodegenerative disease biomarker discovery","volume":"21","author":"Verma","year":"2025","journal-title":"Metabolomics"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.110940_b42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20228","article-title":"Gait analysis detects early changes in transgenic SOD1 (G93A) mice","volume":"32","author":"Wooley","year":"2005","journal-title":"Muscle Nerve: Off. J. Am. Assoc. Electrodiagn. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.110940_b43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00204-023-03660-8","article-title":"Ferroptosis regulation through nrf2 and implications for neurodegenerative diseases","volume":"98","author":"Xiang","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.neuropharm.2026.110940_b44","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106210","article-title":"Nrf2 activation suppresses motor neuron ferroptosis induced by the sod1g93a mutation and exerts neuroprotection in amyotrophic lateral sclerosis","volume":"184","author":"Yang","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.110940_b45","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106210","article-title":"NRF2 activation suppresses motor neuron ferroptosis induced by the SOD1(g93a) mutation and exerts neuroprotection in amyotrophic lateral sclerosis","volume":"184","author":"Yang","year":"2023","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.110940_b46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tins.2020.03.002","article-title":"Proteome homeostasis dysfunction: a unifying principle in als pathogenesis","volume":"43","author":"Yerbury","year":"2020","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.110940_b47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.apsb.2022.07.019","article-title":"Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant sod1 cellular and mouse models of amyotrophic lateral sclerosis","volume":"13","author":"Zhou","year":"2023","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:58:11Z","timestamp":1776758291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0028390826001139"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110940","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ME1 rescues redox-metabolic coordination in ALS: A core effector of NRF2-directed therapy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.110940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110940"}}